Re: Presentation is over
in response to
by
posted on
Jun 09, 2020 08:34AM
Not quite a nothing burger, but close....(Thanks KOO for posting that presentation)
slide 18 contains new material (I think)...The Hazard Ratios for the <60 eGFR cohort were very, very good: (1) MACE; (2) MACE + CHF; and (3) HCHF
Yes, I'm disappointed that the <60 eGFR group showed no improvement in eGFR (cityslicker99 was right), but Apabetalone has a profound positive effect shielding CKD patients from major adverse cardiac events